A*STAR Scientists: Earlier Treatment for Young Patients With Chronic Hepatitis B May Be More Effective in Clearing Virus
1. Scientists from A*STAR’s Singapore Institute for Clinical Sciences (SICS), together with clinical collaborators from London, discovered for the first time that children and young patients with chronic Hepatitis B Virus infection (HBV carriers) do have a protective immune response, contrary to current belief, and hence can be more suitable treatment candidates than previously considered.
2. This discovery by the team of scientists led by Professor Antonio Bertoletti, programme director and research director of the infection and immunity programme at SICS, could lead to a paradigm shift in the current treatment of patients with chronic HBV. The findings were published in Gastroenterology on 1st September.
3. Current guidelines from international liver associations recommend delaying therapy until HBV carriers show clear signs of active liver disease, which generally appear after the age of 30. This is based on two assumptions. One, young patients are unable to react to treatment because they are immune-tolerant to the virus. This means that there is no protective immune response in their body to help them get rid of the virus, and therefore, they will not run the risk of liver damage or inflammation. Two, HBV infection is largely harmless in HBV carriers until active liver disease is apparent.
4. However, Professor Bertoletti and his team showed that young patients are not immune tolerant as they posses HBV-specific T cells with the ability to produce distinct antiviral cytokines that help the body fight against HBV. They also showed that the longer a patient is left untreated, the less effective their immune system becomes against HBV and the less able the patient will be able to clear the virus from their body even when they receive treatment.
5. The scientists demonstrated that the presence of HBV in the body over a long period of time is harmful to the patient due to repeated activation of T-cells which induces a progressive state of T-cell exhaustion, a state of immune system dysfunction that prevents optimal control of the infection and clearance of the virus from the body. Thus, young patients produce an immune response against HBV which is less compromised than that in older patients.
6. Professor Bertoletti said, “Young patients infected with HBV are most at risk of developing chronic HBV but current guidelines mean that they are also the least likely to be treated.However, our findings suggest that it might be better to start treatment early as young people with their stronger immune system, respond better to treatment and are more able to clear the virus.”
7. Prof Judith Swain, Executive Director of SICS, said, “These findings may change the way treatment is applied to patients with HBV in hospitals in Singapore and throughout the world. This is a fine example of how clinicians, physician scientists, and scientists work together to improve healthcare for the public.”
Background on HBV
8. HBV infection affects 400 million people worldwide, 75% of whom reside in Asia. In Singapore, one in every 35 adult is a Hepatitis B carrier. Hepatitis B is the most common infection of the liver that is spread by direct contact with the blood or body fluids of an infected person. Not all HBV carriers display symptoms but lifelong infection carries the risk of serious health complications including cirrhosis, hepatocellular carcinoma, and liver failure.
Notes for Editor:
The research findings described in this news release can be found in the volume 143N 3 issue ofGastroenterology under the title “Preserved T-Cell Function in Children and Young Adults With Immune-Tolerant Chronic Hepatitis B”, by Patrick Kennedy, Elena Sandalova, Juandy Jo, Upkar Gill, Ines Ushiro-Lumb, Anthony Tan, Sandhia Naik, Graham Foster, and Antonoio Bertoletti.
The paper can be accessed at Gastroenterology Journal
More information can be obtained at Biospectrum Asia News